INVESTOR NEWS

Dec 17, 2021

Financial calendar

Financial calendar for Gentian Diagnostics ASA  

Dec 16, 2021

Completed development of SARS CoV-2 antibody assay

Moss, 16 December 2021 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and..

Dec 10, 2021

Share capital increase registered - Correction*

Moss, 9 December 2021 Reference is made to the stock exchange notice from Gentian Diagnostics ASA (the..

Dec 09, 2021

Share capital increase registered

Moss, 9 December 2021 Reference is made to the stock exchange notice from Gentian Diagnostics ASA (the..

Nov 30, 2021

Mandatory notification of trade

Moss, 30 November 2021 Reference is made to the annual general meeting 4 May 2021 where a statement of..

Nov 29, 2021

Share Issue in Connection with Employee Share Purchase Program

Moss, 29 November 2021 Reference is made to the annual general meeting held on 4 May 2021 where a resolution..

Nov 03, 2021

Multicenter study confirms calprotectin’s role in risk stratification in COVID-19

Moss, 3 November 2021   Gentian Diagnostics ASA is pleased to announce that the results from the multicenter..

Nov 01, 2021

New study supports the value of calprotectin in management of COVID-19 patients

Moss, 1 November 2021   Gentian Diagnostics ASA is pleased to announce that the results from a study..

Oct 21, 2021

Third quarter 2021 report

Moss, 21 October 2021: Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..